NCT06652087View on ClinicalTrials.gov

Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Bacterial Overgrowth Syndrome Small BowelHeart Failure with Preserved Ejection Fraction
Interventions
DRUG

Rifaximin

Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days

OTHER

Standard HFpEF treatment

diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor

Trial Locations (1)

Unknown

RECRUITING

Moscow, Moscow

All Listed Sponsors
lead

I.M. Sechenov First Moscow State Medical University

OTHER